论著

过氧化物酶体增殖物激活受体-α激动剂对高脂喂养大鼠脂肪因子表达的♪Supporting info

李 焱, 黄 滨, 程 桦, 梁 真, 刘珊英

中山大学 附属第二医院内分泌科,广州 510120

收稿日期 2006-7-4 修回日期 网络版发布日期 2006-12-29 接受日期

摘要:目的 探讨过氧化物酶体增殖物激活受体-α (PPAR-α)

激动剂非诺贝特对高脂饮食诱导的肥胖SD大鼠胰岛素敏感性和部分脂肪因子表达的影响。方法 随机将大鼠分为3 组(n=10):高脂饮食喂养加非诺贝特治疗组(简称治疗组)、高脂饮食喂养组(简称高脂组)

和标准饮食对照组(简称对照组)。高脂饮食喂养SD大鼠6周后, 以非诺贝特20 mg·kg-1·d-1灌胃治疗4周, 以RT-PCR法半定量测定脂肪组织部分脂肪因子(肿瘤坏死因子-a(TNF-α)、白细胞介素-6(IL-6)、血管紧张素原

(AGT)、血管紧张素Ⅱ1型受体(AT1R)及脂联素)mRNA的表达,同时检测血游离脂肪酸(FFA)、 甘油三脂(TG), 并用稳态模式评估法(HOMA)评价胰岛素抵抗(IR)指数。结果 非诺贝特治疗4周后, 高脂组、 治疗组、对照组的血FFA分别为(2.37±0.60)、(1.59±0.30)、(1.33±0.34) mmol/L, TG分别为

(0.48±0.11)、(0.30±0.04)、(0.36±0.07) mmol/L, HOME-IR指数分别为12.30±3.97、5.03±1.88、4.17±1.27; 脂肪组织TNF-α的mRNA半定量值分别为1.726±1.408、0.713±0.711、0.593±0.382, 脂联素分别为0.660±0.192、 0.949±0.35、0.936±0.130; 上述各指标治疗组与高脂组比较差异均有显著性(P<0.05),

治疗组与对照组比较差异均无显著性(P>0.05); 3组间的AGT、AT1R和IL-6的mRNA表达差异均无显著性(P> 0.05)。结论 PPAR-α激动剂非诺贝特具有改善高脂饮食诱导的脂质异常、 提高胰岛素敏感性以及调节脂肪因子表达的作用。

关键词 过氧化物酶体增殖物激活受体-α 激动剂 脂肪因子 游离脂肪酸 胰岛素抵抗 分类号

Effect of Peroxisome Proliferator-Activated Receptor-α Agonist on Adipokines Expression in Rats Fed with High-fat Diet

LI Yan, HUANG Bin, CHENG Hua, LIANG Zhen, LIU Shan-ying

Department of Endocrinology, The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou 510120, China

Abstract ABSTRACT:Objective To explore the effect of peroxisome proliferator-activated receptor- α (PPAR- α) agonist fenofibrate on adipokines expression in high-fat diet fed SD rats and its relationship to insulin resis- tance (IR). Methods Rats were randomized into three groups (n=10): HD group, fed with high-fat diet; HDF group, fed with high fat diet and treated with fenofibrate; and control group, fed with normal diet. Animals were sacrificed after 4-week follow-up. Plasma lipids, fasting plasma insulin, free fatty acids (FFA), and insulin sensitivity were detected. Reverse transcriptionpolymerase chain reaction was used to semi-quantitatively determine the mRNA expression of adipokines including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), angiotensinogen (AGT), angiotensin II type 1 receptor (AT1R), and adiponectin in brown fat. Results The plasma level of FFA, TG, and homeostatic model approach-IR index were (2.37 ± 0.60) vs (1.59 ± 0.30) vs (1.33 ± 0.34) mmol/L, (0.48 ± 0.11) vs (0.30 ± 0.04) vs (0.36 ± 0.07) mmol/L, and 12.30 ± 3.97 vs 5.03±1.88 vs 4.17±1.27 in the HD group, HDF group, and control group after 4 weeks of treatment with fenofibrate, respectively. The mRNA expressions of TNF- α and adiponectin were 1.726±1.408 vs 0.713±0.711 vs 0.593±0.382 and 0.660±0.192 vs 0.949±0.35 vs 0.936±0.130 in these three groups, which showed significant difference between HD group and HDF group(P < 0.05), while no significant difference between HDF group and control group (P > 0.05). The mRNA expressions of AGT, AT1R, and IL-6 had no significant difference among these three groups (P>0.05). Conclusion PPAR-α agonist fenofibrate may reverse high-fat diet induced lipid abnormalities, improve insulin sensitivity, and regulate the mRNA expressions of TNF- α and adiponectin in adipose tissues.

Key words peroxisome proliferator-activated receptor-α agonist adipokines free fatty acid insulin resistance

扩展功能

本文信息

- ▶ PDF(810KB)
- ▶[HTML全文](0KB)
- ▶参考文献

服务与反馈

- ▶把本文推荐给朋友
- ▶加入我的书架
- ▶加入引用管理器
- ▶复制索引
- ▶ Email Alert
- ▶文章反馈
- ▶浏览反馈信息

相关信息

- ▶ 本刊中 包含
- "过氧化物酶体增殖物激活受体-α"的 相关文章

▶本文作者相关文章

- 黄滨
- 程 桦
- 梁真
- 刘珊英

通讯作者 李 焱 <u>liyan19642002@yahoo.com</u>